Dg/3/17/8443
Total Page:16
File Type:pdf, Size:1020Kb
DG/3/17/8443 1 The World Anti-Doping Code THE 20172018 PROHIBITED LIST INTERNATIONAL STANDARD The official text of the Prohibited List shall be maintained by WADA and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail. The 2018 Prohibited List 30 August 2017 2 This List shall come into effect on 1 January 20172018 The 2018 Prohibited List 30 August 2017 3 THE 20172018 PROHIBITED LIST WORLD ANTI-DOPING CODE Valid 1 January 20172018 In accordance with Article 4.2.2 of the World Anti-Doping Code, all Prohibited Substances shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods M1, M2 and M3. SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES (IN- AND OUT-OF-COMPETITION) PROHIBITED SUBSTANCES S0. NON-APPROVED SUBSTANCES Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use (e.g. drugs under pre-clinical or clinical development or discontinued, designer drugs, substances approved only for veterinary use) is prohibited at all times. S1. ANABOLIC AGENTS Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS) a. Exogenous* AAS, including: 1-androstenediol (5α-androst-1-ene-3β,17β-diol ); 1-androstenedione (5α-androst-1-ene-3,17-dione); 1-androsterone (3α-hydroxy-5α-androst-1-ene-17-one); 1-testosterone (17β-hydroxy-5α-androst-1-en-3-one); The 2018 Prohibited List 30 August 2017 4 4-hydroxytestosterone (4,17β-dihydroxyandrost-4-en-3-one); bolandiol (estr-4-ene-3β,17β-diol ); bolasterone; calusterone; clostebol; danazol ([1,2]oxazolo[4',5':2,3]pregna-4-en-20-yn-17α-ol); dehydrochlormethyltestosterone (4-chloro-17β-hydroxy-17α-methylandrosta- 1,4-dien-3-one); desoxymethyltestosterone (17α-methyl-5α-androst-2-en-17β-ol); drostanolone; ethylestrenol (19-norpregna-4-en-17α-ol); fluoxymesterone; formebolone; furazabol (17α-methyl [1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); gestrinone; mestanolone; mesterolone; metandienone (17β-hydroxy-17α-methylandrosta-1,4-dien-3-one); metenolone; methandriol; methasterone (17β-hydroxy-2α,17α-dimethyl-5α-androstan-3-one); methyldienolone (17β-hydroxy-17α-methylestra-4,9-dien-3-one); methyl-1-testosterone (17β-hydroxy-17α-methyl-5α-androst-1-en-3-one); methylnortestosterone (17β-hydroxy-17α-methylestr-4-en-3-one); methyltestosterone; metribolone (methyltrienolone, 17β-hydroxy-17α-methylestra-4,9,11-trien-3- one); mibolerone; norboletone; norclostebol; norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone; prostanozol (17β-[(tetrahydropyran-2-yl)oxy]-1'H-pyrazolo[3,4:2,3]-5α- androstane); quinbolone; stanozolol; stenbolone; tetrahydrogestrinone (17-hydroxy-18a-homo-19-nor-17α-pregna-4,9,11-trien- 3-one); trenbolone (17β-hydroxyestr-4,9,11-trien-3-one); and other substances with a similar chemical structure or similar biological effect(s). The 2018 Prohibited List 30 August 2017 5 b. Endogenous** AAS when administered exogenously: 19-norandrostenediol (estr-4-ene-3,17-diol); 19-norandrostenedione (estr-4-ene-3,17-dione); androstanolone (5α-dihydrotestosterone, 17β-hydroxy-5α-androstan-3-one); androstenediol (androst-5-ene-3β,17β-diol); androstenedione (androst-4-ene-3,17-dione); boldenone; Formatted: German (Germany) boldione (androsta-1,4-diene-3,17-dione); dihydrotestosterone (17β-hydroxy-5α-androstan-3-one); nandrolone (19-nortestosterone); prasterone (dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one); testosterone; and their metabolites and isomers, including but not limited to: 3β-hydroxy-5α-androstan-17-one; 5α-androst-2-ene-17-one; 5α-androstane-3α,17α-diol; Formatted: English (United States) 5α-androstane-3α,17β-diol; Formatted: English (United States) 5α-androstane-3β,17α-diol; Formatted: English (United States) 5 -androstane-3 ,17 -diol; α β β Formatted: English (United States) 5β-androstane-3α,17β-diol; Formatted: English (United States) 7α-hydroxy-DHEA; 7β-hydroxy-DHEA; Formatted: English (United States) 4-androstenediol (androst-4-ene-3β,17β-diol); Formatted: English (United States) 5-androstenedione (androst-5-ene-3,17-dione); 7-keto-DHEA; 19-norandrosterone; 19-noretiocholanolone; androst-4-ene-3α,17α-diol; androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol; androsterone; epi-dihydrotestosterone; epitestosterone; etiocholanolone. Formatted: Font: Not Bold 2. Other Anabolic Agents Including, but not limited to: The 2018 Prohibited List 30 August 2017 6 Clenbuterol, selective androgen receptor modulators (SARMs, e.g. andarine and, LGD-4033, ostarine and RAD140), tibolone, zeranol and zilpaterol. Formatted: Font: Bold For purposes of this section: * “exogenous” refers to a substance which is not ordinarily produced by the body naturally. ** “endogenous” refers to a substance which is ordinarily produced by the body naturally. The 2018 Prohibited List 30 August 2017 7 S2. PEPTIDE HORMONES, GROWTH FACTORS, RELATED SUBSTANCES AND MIMETICS The following substances, and other substances with similar chemical structure or Formatted: Kern at 12 pt similar biological effect(s), are prohibited: Formatted: Normal, Left, Indent: Left: 0", First line: 0.5" Formatted: English (United Kingdom), Kern at 12 pt 1. Erythropoietins (EPO) and agents affecting erythropoiesis, including, but Formatted: Font: Not Bold, Kern at 12 pt not limited to: Formatted: Font: Not Bold, Kern at 12 pt Formatted: Kern at 12 pt 1. 1.1 Erythropoietin-Receptor agonists: Formatted: Font: Not Bold, Kern at 12 pt 1.1 Erythropoiesis-Stimulating Agents (ESAs) includingAgonists, Formatted: Kern at 12 pt e.g. Formatted: Font: Not Bold, Kern at 12 pt darbepoietinDarbepoetins (dEPO); Formatted: Kern at 12 pt erythropoietins (EPO); Formatted: Font: Not Bold, Kern at 12 pt EPO based constructs [EPO-Fc; Formatted: Font: Not Bold, Kern at 12 pt EPO-mimetic peptides (EMP), e.g. CNTO 530 and peginesatide; Formatted: Normal, Left, Indent: Left: 0.51", First line: 0" GATA inhibitors, e.g. K-11706; Formatted: Font: Not Bold, English (United Kingdom), Kern , methoxy polyethylene glycol-epoetin beta (CERA);)]; EPO-mimetic at 12 pt agents and their constructs (e.g. CNTO-530, peginesatide). Formatted: English (United Kingdom), Kern at 12 pt transforming Growth Factor-β (TGF-β) inhibitors, e.g. Formatted: Kern at 12 pt sotatercept, luspatercept; Formatted: Kern at 12 pt Formatted: Normal, Left, Indent: Left: 0.51", Hanging: 1.2 Non-erythropoietic EPO-Receptor agonists, e.g. 0.24" ARA-290; Formatted: Font: Bold, Kern at 12 pt asialo EPO; carbamylated EPO; Formatted: Kern at 12 pt Formatted: English (United Kingdom), Kern at 12 pt Hypoxia-inducible factor (HIF) stabilizersactivating agents, e.g. Formatted: Font: Bold, English (United Kingdom), Kern at 2. Argon; cobalt,; molidustat and; roxadustat (FG-4592); and HIF 12 pt activators, e.g. argon and xenon;. Formatted: English (United Kingdom), Kern at 12 pt Formatted: English (United Kingdom), Kern at 12 pt 1.3. GATA inhibitors, e.g. Formatted: Normal, Left, Indent: Left: 0.51", No bullets or K-11706. numbering Formatted: Font: Not Bold, English (United Kingdom), Kern 1.4 TGF-beta (TGF-β) inhibitors, e.g. at 12 pt Luspatercept; sotatercept. Formatted: English (United Kingdom), Kern at 12 pt Formatted: English (United Kingdom), Kern at 12 pt 1.5 Innate repair receptor agonists, e.g. Formatted: English (United Kingdom), Kern at 12 pt Asialo EPO; carbamylated EPO (CEPO). Formatted: English (Canada) Formatted: English (United Kingdom), Kern at 12 pt Formatted: English (United Kingdom), Kern at 12 pt 2. Peptide Hormones and Hormone Modulators, : Formatted: Font: Not Bold, Kern at 12 pt 2.1 Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH) and Formatted: Kern at 12 pt their releasing factors, e.g. buserelin Formatted: Normal, Left, Indent: Left: 0.51", Hanging: 0.24", Tab stops: Not at 0.25" Formatted: Font color: Auto, Kern at 12 pt The 2018 Prohibited List 30 August 2017 8 Buserelin, deslorelin, gonadorelin and, goserelin, leuprorelin, Formatted: Font: Not Bold nafarelin and triptorelin, in males; Formatted: Font color: Auto Formatted: Font: Bold, Font color: Auto 4. Formatted: Indent: Left: 0.59", First line: 0", Tab stops: 2.2 Corticotrophins and their releasing factors, e.g. corticorelin; 0.59", Left + 0.69", Left + Not at 0.25" + 0.3" Formatted: Indent: Left: 0", First line: 0", Tab stops: 0.1", 5. Corticorelin; Left + 0.59", Left + Not at 0.25" Formatted: Font: Not Bold 2.3 Growth Hormone (GH) and), its fragments and releasing factors, Formatted: Indent: Left: 0.59", First line: 0", Tab stops: including, but not limited to: 0.59", Left + 0.69", Left + Not at 0.25" Growth Hormone fragments, e.g. AOD-9604 and hGH 176-191; Growth Formatted: Font color: Black Hormone Releasing Hormone (GHRH) and its analogues, e.g. CJC-1293, CJC-1295, sermorelin and tesamorelin; Growth Hormone Secretagogues (GHS), e.g. ghrelin and ghrelin mimetics, e.g. anamorelin and, ipamorelin; and tabimorelin; GH-Releasing Peptides (GHRPs), e.g. Formatted: Indent: Left: 0.59", First line: 0", Tab stops: alexamorelin, GHRP-6, hexarelin and 1, GHRP-2 (pralmorelin (GHRP- 0.59", Left + Not at 0.25" 2).), GHRP-3, GHRP-4, GHRP-5, GHRP-6, and hexarelin. Formatted: Font color: Auto Additional prohibited growth factors: Formatted: Font color: Auto Formatted: Font: Not Bold, Font color: Auto Formatted: Font color: Auto 3. Growth Factors and Growth Factor Modulators, including, but not limited Formatted: Font: Not Bold, Font color: Auto to: Formatted: Font color: Auto Formatted: Font: Not Bold, Font color: Auto Fibroblast Growth Factors (FGFs); Formatted: Font color: Auto Hepatocyte Growth Factor (HGF); Formatted: Font: Not Bold, Font color: Auto Insulin-like Growth Factor-1 (IGF-1) and its analogues; Mechano Growth Factors (MGFs); Formatted: Font: Not Bold Platelet-Derived Growth Factor (PDGF); Formatted: Font: Not Bold Thymosin-β4 and its derivatives e.g.